STAT+: Amazon health feature can accurately assess users’ mobility, study finds
As Amazon works to shoulder its way into health care, a new study — funded…
Category: STAT+
STAT+: Why Illumina has a merger mess of it own making
For Illumina, the leading maker of DNA sequencing equipment, there was bad news and worse…
STAT+: Bayer agrees to $40 million settlement over kickbacks and downplaying drug safety risks
After nearly two decades of litigation, Bayer agreed to pay $40 million to settle a…
STAT+: Pharmalittle: Illumina deal for Grail is blocked after EU veto; CVS buys Signify to expand into house calls
Good morning, everyone, and nice to see you again after a much-welcomed and extended break…
STAT+: Doctors, seniors groups flag concerns with Medicare Advantage
Doctors, patients, and seniors groups are airing new grievances about Medicare Advantage, arguing the growing…
STAT+: How a tool to map computer viruses came to power biology research
When mathematicians Leland McInnes and John Healy walked into their work’s annual “Big Dig” —…
STAT+: Pharmalittle: Illumina faces more challenges after winning FTC case; Novo Nordisk buys Forma Therapeutics
Good morning, everyone. I’m Jason Mast, the last of the understudies filling in while Ed…
STAT+: Pharmalittle: FDA authorizes new Covid boosters; a setback for federal efforts to regulate stem cell clinics
Good morning. This is Jonathan with you once more. We’re now close enough to the…
STAT+: Calm’s head of science departs amid a shakeup at meditation app maker
In 2021, Jennifer Huberty left her post in academia to become the first full-time head…
STAT+: Pharmalittle: An emerging star in biotech investment; U.S. government expected to stop paying for Covid shots next year
Good morning from San Diego. I’m Jonathan Wosen, STAT’s West Coast biotech reporter, and I’m…
STAT+: One Medical founder Tom Lee on the Amazon deal and striking the right balance with virtual care
Virtual care companies face increasing churn as telehealth visits sink below their pandemic-era peak, forcing…
STAT+: Once a small player among biotech VCs, Mubadala Capital Ventures is punching above its weight
At the start of 2021, blue-chip biotech investor ARCH Venture Partners and a relatively unknown…
STAT+: In a new lawsuit, pharma-backed patient groups fight federal rule around copay coupons
Three patient advocacy groups are suing the Biden administration to challenge a federal regulation they…
STAT+: Pharmalittle: FDA expected to authorize new Covid-19 boosters; Biden administration signs a deal to support monkeypox vaccine manufacturing
Good morning, everyone. I’m Allison DeAngelis, and I’m here to lead you through Tuesday’s news….
STAT+: Pharmalittle: The ‘godfather’ of biotech trying to save Biogen; pharma companies grapple with ADHD drug shortages
Happy Monday, folks — Allison DeAngelis here. Ed is away from the Pharmalot campus this…
STAT+: As medical device companies look to snap up Medicare dollars, potential conflicts lurk
Medicare is expected to pay more than $86 billion next year for care given in…
.jpg)
STAT+: Fed up with costly, onerous recertification, doctors are turning to an alternative board
While taking the exam to renew his physician specialty certification, pulmonologist Jordan Metcalf got hung…
STAT+: For the ‘godfather’ of biotech, saving Biogen is the final act of a singular career
In the history of the global pharmaceutical industry, there have been many big thinkers, brash…
STAT+: Moderna’s suing Pfizer? Wow! OK, now take a deep breath.
It’s the stuff that headline writers’ dreams are made of: Moderna is suing Pfizer and…
STAT+: Pharmalittle: Moderna sues Pfizer over Covid-19 vax patents; White House directs quick access to federally funded research
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Centene agrees to pay $33 million to resolve another state probe into its pharmacy benefits business
Centene, one of the largest health insurers in the U.S., agreed to pay $33 million…
STAT+: Why Amazon and other corporate giants are in a bidding war for home health technology
The bidding war over Signify Health — a health technology business that could fetch multibillion-dollar…
STAT+: Pharmalittle: House report shows Trump sought to pressure FDA on Covid response; Pfizer Covid pill provides little benefit to younger adults
Rise and shine, everyone, another busy day is on the way. Or will it be…
STAT+: Pfizer’s experimental RSV vaccine protects older adults in study
A vaccine Pfizer is developing protected older adults against the respiratory syncytial virus, or RSV,…
STAT+: Pharmalittle: AstraZeneca may exit the vaccine business; Bavarian Nordic looks at expired monkeypox vax doses to boost supplies
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: How a long-overlooked protein could remake neuroscience drug discovery — or plunge the FDA into controversy
So, imagine you get punched in the head. Not once, but a bunch of times….
STAT+: Pharmalittle: Biden plan to stretch monkeypox vax supplies hits problems; Pfizer and BioNTech ask FDA to clear Covid shot for variants
Top of the morning to you, and a fine one it is. After a much-needed…
STAT+: Faster drug approval route sparks investment in rare kidney disease treatments
Recent years have seen a surge of research into rarer forms of kidney disease, with…
Opinion: STAT+: How machine learning and automation can solve biomanufacturing scale-up challenges
Biomanufacturing has produced important materials, ingredients, therapeutics, and more for decades, yet it is still…
STAT+: OrbiMed tumbles from the top of STAT’s biotech venture capital performance ranking
Noted biotech investment firm OrbiMed slid from first place to 14th in STAT’s latest annual…
Pfizer seeks authorization for updated Covid vaccine, without fresh clinical trial data
Pfizer and BioNTech said Monday that they have asked the Food and Drug Administration to…
STAT+: Major Indian generic drugmaker closes a U.S. facility after years of manufacturing problems
After a decade of manufacturing problems, a U.S. federal court ordered a unit of Wockhardt,…
STAT+: Pharmalittle: Murky online market for abortion pills is thriving; more ‘cash pay’ pharmacies decline insurance in the U.S.
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: How North Carolina hospitals justify thwarting Medicaid expansion
North Carolina hospitals just helped kill a major expansion of the state’s Medicaid program. Both…
STAT+: Biden administration largely stands firm on its method for resolving surprise billing disputes
The Biden administration largely stood firm on its plan for resolving disputes over surprise medical…
STAT+: FDA scolds Sun Pharma for allegedly backdating documents and fudging records for collecting drug samples
Sun Pharmaceutical, which is one of the largest purveyors of generic drugs, allegedly falsified various…
STAT+: FDA approves Axsome’s fast-acting treatment for major depression
After a lengthy review, the Food and Drug Administration approved a fast-acting depression treatment from…
STAT+: Pharmalittle: Biden plan to shift cost of Covid-19 products to consumers; U.S. company to help with monkeypox shot production
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Medicare may eventually negotiate some drug prices, but Colorado still wants to import medicines from Canada
The Biden administration may have signed a law designed to lower prescription drug prices, but…
STAT+: ‘We’re finally here’: Harvard graduate spearheads custom gene therapy for younger brother
Richard Horgan has waited for this moment for more than three years. Last month, the…
STAT+: Pharmalittle: FDA approves a gene therapy for a rare blood disorder; pharmacy chains ordered to pay $650 million over opioid crisis
Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy…
STAT+: Pharma’s likely to sue over Medicare negotiation. Here are the arguments they might use
WASHINGTON — Democrats finally achieved a win over the pharmaceutical industry this month when they…
STAT+: Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder
The Food and Drug Administration on Wednesday approved a new treatment that delivers a potentially…
STAT+: ‘A blind eye’: NIH fails to ensure clinical trial results are reported and funds researchers who don’t file results
The U.S. National Institutes of Health failed to ensure that results of roughly half of…
STAT+: Pharmalittle: Endo files for bankruptcy protection due to opioid suits; first Zantac lawsuit dropped, giving GSK a boost
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Blueprint Medicines drug reduces mastocytosis symptoms in a new study, meeting investor expectations
A drug made by Blueprint Medicines markedly improved symptoms of a rare immune system disorder…
STAT+: Ex-Google CEO’s VC firm brings in hype-busting researcher to expand its biotech investments
Innovation Endeavors, the venture capital firm co-founded by former Google chairman and CEO Eric Schmidt,…
STAT+: Hospital mergers that dodge antitrust scrutiny lead to dramatically higher prices, study finds
Hospitals that merge under state regulations that shield them from federal scrutiny tend to eventually…
STAT+: Frustrated with nature’s biomarkers for cancer, biologists try making their own
On Target is a recurring feature from STAT that dives deep into the most promising…
STAT+: Cepheid faces fresh criticism over the pricing of its TB diagnostics
A controversy has broken out over a diagnostic for tuberculosis that, until recently, had been…